UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
FORM 8-K
Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
____________________
Date of report (Date of earliest event reported): October 1, 2019
Amyris, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-34885 | 55-0856151 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| 5885 Hollis Street, Suite 100, Emeryville, CA | 94608 | ||
| (Address of principal executive offices) | (Zip Code) |
| (510) 450-0761 | ||
| (Registrant’s telephone number, including area code) |
| (Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2 below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.0001 par value per share | AMRS | Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition. |
On October 1, 2019, Amyris, Inc. (the “Company”) issued a press release announcing certain of the Company’s financial results for the six months ended June 30, 2019. A copy of this press release, entitled “Amyris Provides Highlights of First Half 2019 Financial Results”, is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
The following exhibit is furnished herewith:
| Exhibit Number |
Description |
| 99.1 | Press release, issued October 1, 2019, entitled “Amyris Provides Highlights of First Half 2019 Financial Results” |
The information in this report, including
the exhibit hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,
or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the
Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless
expressly incorporated by specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AMYRIS, INC. | |||
| Date: October 1, 2019 | By: | /s/ Kathleen Valiasek | |
| Kathleen Valiasek | |||
| Chief Business Officer | |||
Exhibit 99.1
Amyris Provides Highlights of First Half 2019 Financial Results
Delivers 134% Revenue Growth Over First Half 2018; Files 2018 Form 10-K
Posts First-Half 2019 GAAP Revenue of $77.1 million; Cannabinoid Development Program Exceeds Expectations
EMERYVILLE, Calif., October 1, 2019 -- Amyris, Inc. (Nasdaq:AMRS) today provided highlights of its business and financial results for the first half of 2019 ended June 30, 2019, which it will review during a conference call after market close on Wednesday, October 2, 2019. The company also noted that it is has filed its 2018 Form 10-K and expects to file its Form 10-Qs for the first and second quarters of 2019 before the conference call on Wednesday. As a result of completing these filings, the company believes that it will have filed all of its delinquent SEC filings and be back in compliance with Nasdaq listing rules.
First-Half 2019 Financial Results and Recent Business Highlights
| · | First-half 2019 GAAP revenue of $77.1 million with very strong gross margin compared to total first-half 2018 GAAP revenue of $32.9 million |
| · | Successful launch of Pipette baby care brand raising the bar for clean and safe baby care products |
| · | International expansion of Biossance, one of the fastest growing clean beauty skincare brands in the US, gets a strong start upon entry into Australian and New Zealand markets |
| · | Expansion of ADL Bionatur Solutions (ADL) manufacturing agreement and execution of strategic supply agreement with Raízen, the largest sugar producer in the world, to provide additional, cost-effective manufacturing capacity to meet growth demand |
| · | Appointment of two new board members with significant experience in building high growth product and consumer companies ‒ Jim McCann, founder and chairman of 1-800-Flowers, and Lisa Qi, founder and CEO of Daling Family e-commerce platform in China |
| · | Receipt of first milestone payment of $10 million in March 2019 for successful cannabinoid (CBD) development; good progress being made toward second major milestone. |
“We are pleased with our financial results for the first-half of 2019,” said John Melo, Amyris President and CEO. “Our teams have delivered higher volumes to support stronger demand this year and in the second half they are continuing at record levels. We remain confident that we will exceed our revenue goal for 2019. Our $300 million cannabinoid development collaboration is also exceeding our expectations. We are now on track to be the first company to produce multiple cannabinoids at commercial scale that are fermentation derived in 2020.”
The company will hold its conference call to discuss financial results and business highlights for the first half of 2019, as well as provide an update on the company's business and outlook, at 4:30 p.m. ET (1:30 p.m. PT) on Wednesday, October 2, 2019. The company will not be issuing a customary earnings release on its financial results prior to the call, as the company expects that the financial results for the first and second quarters of 2019 will have been fully disclosed via the filing of required Form 10-Qs.
Conference Call:
Wednesday, October 2, 2019, 4:30 p.m. ET/1:30 p.m. PT
Dial-in Number:
(877) 870-4263 (U.S. & International)
Participants should ask to be joined to the Amyris, Inc. call.
Audio Webcast:
A live webcast of the call will be available online on the Amyris website. To listen via live webcast, please visit: http://investors.amyris.com.
A replay of the webcast will be available on the Investor Relations section of the company's website approximately two hours after
the conclusion of the call.
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products and services across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.
Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed
to be forward-looking statements. These forward-looking statements include, among other things, statements regarding the expected
filing of Amyris’s Form 10-Qs for the first and second quarters of 2019, including the timing thereof and the related disclosure
of Amyris’s financial results for the first and second quarters of 2019, Amyris’s anticipated regaining compliance
with Nasdaq listing rules, including the timing thereof, expected 2019 revenue and business growth, including growth in demand
for, and production of, Amyris products, and anticipated growth of Biossance and Pipette brands and development and commercial
production of cannabinoid products. These statements are based on management's current expectations and actual results and future
events may differ materially due to risks and uncertainties, including risks related to Amyris's liquidity and ability to fund
operating and capital expenses, risks related to potential delays or failures in development, production and commercialization
of products, risks related to Amyris's reliance on third parties, and other risks detailed from time to time in filings Amyris
makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current
Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether
as a result of new information, future events, or otherwise.
Amyris, the Amyris logo, Biossance, and No Compromise are trademarks or registered trademarks of Amyris, Inc. in the U.S. and/or other countries.
Contact:
Peter DeNardo
Director, Investor Relations and Corporate Communications
Amyris, Inc.
+1 (510) 740-7481
investor@amyris.com